Your session is about to expire
← Back to Search
Electronic Decision Support Tool
Electronic decision support for deprescribing (MedSafer tool) for Deprescribing (E-CARE Trial)
N/A
Waitlist Available
Led By Emily McDonald, MDCM
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
E-CARE Trial Summary
This trial will test the feasibility of using an electronic tool to generate real-time reports on patients' drug use, displayed to clinicians in the electronic medical record.
Eligible Conditions
- Deprescribing
- Overmedication
- Adverse Drug Reactions
E-CARE Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Proportion of patients with one or more PIM (potentially inappropriate medication) reduced or stopped
Secondary outcome measures
Sustainability; quality of life; sleep quality; falls; transfer to acute hospital; hip fractures; and delirium
Other outcome measures
Cost savings
E-CARE Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention: MedSaferExperimental Treatment1 Intervention
In the intervention phase, the MedSafer feature will become accessible in MED e-care for the physicians, pharmacists and nurses. This feature will provide health care professionals with individualized and prioritized deprescribing opportunities: a) identifying the medication, b) explaining why that medication is potentially inappropriate and c) providing instructions on how to safely stop/taper the medication. The user will review these opportunities and appropriate candidate medications for deprescribing can then be tapered or stopped directly in the EMR. During the intervention phase, all patients will receive the educational (EMPOWER) brochures as applicable to the medications they are taking (PPI, sedative-hypnotic, antihistamine, antipsychotic, sulfonylurea, NSAID, opioid/narcotic).
Group II: Control: Baseline (no MedSafer)Active Control1 Intervention
During the control phase, the MedSafer application programming interface will not be accessible to the caretakers at the aged care facilities (ACF). This serves to obtain baseline deprescribing levels for each ACF.
Find a Location
Who is running the clinical trial?
Centre for Aging and Brain Health InnovationOTHER
15 Previous Clinical Trials
5,200 Total Patients Enrolled
OMNI Health CareUNKNOWN
MED e-care Healthcare SolutionsUNKNOWN
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
To what extent is the participation rate of this clinical trial?
"Confirmed. Clinicaltrials.gov confirms that this medical experiment, which was initially published on January 1st 2021, is actively enrolling participants. 300 individuals need to be enrolled from one centre for the trial's completion."
Answered by AI
Are there any opportunities currently available to join this research endeavor?
"Affirmative. Clinicaltrials.gov attests that this clinical trial, established on the 1st of January 2021, is recruiting participants. This study requires 300 enrolled patients and will take place at one location."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger